Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Theramine + naproxen is a combination therapy consisting of Theramine, a medical food formulated for the dietary management of pain and inflammatory disorders, and naproxen, a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain and inflammation. Theramine is designed to address metabolic processes associated with chronic pain conditions such as back pain, fibromyalgia, neuropathic pain, and inflammatory pain[2][3]. Naproxen works by inhibiting cyclooxygenase enzymes (COX-1 and COX-2), thereby reducing prostaglandin synthesis involved in inflammation and pain signaling. Clinical studies have shown that the combination may provide superior functional improvement compared to naproxen alone while potentially mitigating some adverse effects associated with NSAID monotherapy[3]. The combination is intended for patients who require both dietary management of underlying metabolic imbalances contributing to chronic pain as well as pharmacological anti-inflammatory action.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on theramine + naproxen.